The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 3, 2003, Pages 219-228

  Kuiken, Sjoerd D ^a   Tytgat, Guido N J ^a   Boeckxstaens, Guy E E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGORAPHOBIA; ANXIETY; ARTICLE; BAROSTAT; CLINICAL ARTICLE; CLINICAL TRIAL; COLON DILATATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSTILITY; HUMAN; INTESTINE PRESSURE; IRRITABLE COLON; MALE; NAUSEA; PAIN ASSESSMENT; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM; SLEEP DISORDER; SOMATIZATION; STATISTICAL ANALYSIS; VERTIGO;

EID: 0038418617     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(03)70039-1     Document Type: Article

References (40)

1. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
2. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001;120:652-668.
3. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112:2120-2137.
4. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48:272-282.
5. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-317.
6. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-1156.
7. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271-293.
8. Cervero F, Laird JM. Visceral pain. Lancet 1999;353:2145-2148.
9. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999;116:38-45.
10. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171-1178.
11. Bharucha AE, Camilleri M, Zinsmeister AR, Hanson RB. Adrenergic modulation of human colonic motor and sensory function. Am J Physiol 1997;273:G997-G1006.
12. Poitras P, Riberdy PM, Plourde V, Boivin M, Verrier P. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002;47:914-920.
13. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998;275:G460-G466.
14. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med 2002;162:19-24.
15. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980-990.
16. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001;13:31-41.
17. Coquoz D, Porchet HC, Dayer P. Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Clin Pharmacol Ther 1993;54:339-344.
18. Thompson WG, Dotefall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989;2:92-95.
19. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
20. Svedlund J, Sjodin I, Dotefall G. GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-134.
21. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 1973;9:13-28.
22. Arrindell WA, Ettema H. Dimensionele structuur, betrouwbaarheid en validiteit van de Nederlandse bewerking van de Symptom Checklist (SCL-90); gegevens gebaseerd op een fobische en een 'normale' populatie [Dutch]. Nederlands Tijdschrift voor de Psychologie 1981;77-108.
23. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002;51(suppl 1):167-171.
24. Korzeniewska-Rybicka I, Plaznik A. Analgesic effect of antidepressant drugs. Pharmacol Biochem Behav 1998;59:331-338.
25. Singh VP, Jain NK, Kulkarni SK. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res 2001;915:218-226.
26. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity: facts, speculations, and challenges. Gut 2001;48:125-131.
27. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998;42:807-813.
28. Cannon RO III, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, Geraci MF, Black BC, Uhde TW, Waclawiw MA. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994;330:1411-1417.
29. Wald A. Irritable bowel syndrome. Curr Treat Options Gastroenterol 1999;2:13-19.
30. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-416.
31. Efremova I, Asnis G. Antidepressants in depressed patients with irritable bowel syndrome. Am J Psychiatry 1998;155:1627-1628.
32. Kirsch MA, Louie AK. Paroxetine and irritable bowel syndrome. Am J Psychiatry 2000;157:1523-1524.
33. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-1159.
34. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-1666.
35. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-1040.
36. Camilleri M. Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut 2002;51(suppl 1): 134-140.
37. Whitehead WE, Delvaux M. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract: The Working Team of Glaxo-Wellcome Research, UK. Dig Dis Sci 1997;42:223-241.
38. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific: evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995;40:1607-1613.
39. Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997;92:954-959.
40. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):1143-1147.